// App-Quantinova.ai

FRI0123 : SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS

Researchers

Presenter

  • M. C. Genovese

Principal Investigators

  • J. S. Smolen

  • T. Takeuchi

  • G. R. Burmester

  • W. Deberdt

  • D. Schlichting

  • H. Song

  • D. Mo

  • C. Walls

  • K. Winthrop

Medical Centers

  • Stanford, Division of Immunology and Rheumatology, Stanford, United States of America

  • Medical University of Vienna Clinical Division of Oncology, Department of Medicine, Vienna, Austria

  • The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Department of Endoscopy, Tokyo, Japan

  • Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

  • Eli Lilly and Company Indianapolis IN United States

  • Syneos Health, Morrisville, NC, United States of America

  • Oregon Health & Science University, Portland, United States of America

Locations

  • United States

  • Austria

  • Japan

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved